Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2021 Results - Earnings Call Transcript
10:13pm, Wednesday, 11'th Aug 2021
Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2021 Results - Earnings Call Transcript
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Lags Revenue Estimates
06:38pm, Wednesday, 11'th Aug 2021
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.08% and -13.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 11'th Aug 2021
Topline Data from XEN1101 Phase 2b “X-TOLE” Clinical Trial Anticipated Late September to Mid-October 2021
Xenon Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
05:53pm, Tuesday, 10'th Aug 2021
BURNABY, British Columbia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one in
Xenon Pharmaceuticals to Participate at the William Blair Biotech Focus Conference 2021
08:45am, Tuesday, 13'th Jul 2021
BURNABY, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in a virtual fir
Webinar to be broadcast live on Monday, July 12, 2021 beginning at 10 am ET Webinar to be broadcast live on Monday, July 12, 2021 beginning at 10 am ET
Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders
05:45pm, Thursday, 03'rd Jun 2021
BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Ann
Xenon Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
04:01pm, Monday, 31'st May 2021
BURNABY, British Columbia, May 31, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive manageme
Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q1 2021 Results - Earnings Call Transcript
11:14pm, Tuesday, 11'th May 2021
Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q1 2021 Results - Earnings Call Transcript
Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
04:01pm, Tuesday, 11'th May 2021
Topline Data from XEN1101 Phase 2b “X-TOLE” Clinical Trial Anticipated by End of Third Quarter of 2021
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
04:03pm, Thursday, 08'th Apr 2021
BURNABY, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive manage
Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day
04:05pm, Monday, 29'th Mar 2021
BURNABY, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the Company will participate in
BURNABY, British Columbia, March 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announ
Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
12:49am, Wednesday, 10'th Mar 2021
BURNABY, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten publ
Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares
04:05pm, Tuesday, 09'th Mar 2021
BURNABY, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwrit
